Business Description
Instil Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US45783C2008
Total Employee Number:
17Description
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.88 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.77 | |||||
Debt-to-EBITDA | -2.03 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 33.5 | |||||
3-Year EPS without NRI Growth Rate | 39 | |||||
3-Year FCF Growth Rate | 44.5 | |||||
3-Year Book Growth Rate | -33 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 16.36 | |||||
9-Day RSI | 25.23 | |||||
14-Day RSI | 30.17 | |||||
3-1 Month Momentum % | -5.15 | |||||
6-1 Month Momentum % | 7 | |||||
12-1 Month Momentum % | -76.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 39.87 | |||||
Quick Ratio | 39.87 | |||||
Cash Ratio | 15.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.4 | |||||
Shareholder Yield % | 2.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -38.11 | |||||
ROA % | -21.85 | |||||
ROIC % | -34.26 | |||||
3-Year ROIIC % | -159.14 | |||||
ROC (Joel Greenblatt) % | -38.71 | |||||
ROCE % | -20.08 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.44 | |||||
Price-to-Tangible-Book | 0.44 | |||||
EV-to-EBIT | -1.41 | |||||
EV-to-Forward-EBIT | -0.82 | |||||
EV-to-EBITDA | -1.41 | |||||
EV-to-FCF | -1.76 | |||||
| Price-to-Net-Current-Asset-Value | 0.5 | |||||
Earnings Yield (Greenblatt) % | -70.92 | |||||
FCF Yield % | -69.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TIL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Instil Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -7.04 | ||
| Beta | 2.3408 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 1.73 | ||
| Volatility % | 66.88 | ||
| 14-Day RSI | 30.17 | ||
| 14-Day ATR ($) | 0.24806 | ||
| 20-Day SMA ($) | 7.54175 | ||
| 12-1 Month Momentum % | -76.3 | ||
| 52-Week Range ($) | 5.67 - 33.833 | ||
| Shares Outstanding (Mil) | 6.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Instil Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Instil Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 109 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 17 days | ||
| General meeting for 2026 | 2026-06-11 11:00 | 7.98 (-1.87%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 8.05 (-1.47%) | ||
| Annual report for 2025 | 2026-03-27 | 8.36 (-0.48%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 8.36 (-0.48%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 14.99 (-4.83%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 26.83 (-5.33%) | ||
| Jefferies Global Healthcare Conference | 2025-06-05 16:20 | 34.40 (+18.87%) | ||
| General meeting for 2025 | 2025-05-28 11:00 | 24.21 (+7.77%) |
Show
Entries
Instil Bio Inc Frequently Asked Questions
What is Instil Bio Inc(TIL)'s stock price today?
The current price of TIL is $7.20. The 52 week high of TIL is $33.83 and 52 week low is $5.67.
When is next earnings date of Instil Bio Inc(TIL)?
The next earnings date of Instil Bio Inc(TIL) is 2026-08-13 Est..
Does Instil Bio Inc(TIL) pay dividends? If so, how much?
Instil Bio Inc(TIL) does not pay dividend.
Guru Commentaries on NAS:TIL
No articles.
Press Release
Articles on Instil Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers